Full text
PDF![1121](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ac1/438451/d091167b980f/jcinvest00612-0069.png)
![1122](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ac1/438451/61495d935c61/jcinvest00612-0070.png)
![1123](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ac1/438451/4db492db3140/jcinvest00612-0071.png)
![1124](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ac1/438451/708c5b101049/jcinvest00612-0072.png)
![1125](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ac1/438451/fe1ab75b9395/jcinvest00612-0073.png)
![1126](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ac1/438451/c2b8a82c58c7/jcinvest00612-0074.png)
![1127](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ac1/438451/24d87924b11e/jcinvest00612-0075.png)
![1128](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ac1/438451/25dd6838279c/jcinvest00612-0076.png)
![1129](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ac1/438451/ef2929ac9bb7/jcinvest00612-0077.png)
![1130](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ac1/438451/9f69cdb13c61/jcinvest00612-0078.png)
![1131](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ac1/438451/0bae1baed0d2/jcinvest00612-0079.png)
![1132](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ac1/438451/3c4e11d3ba9b/jcinvest00612-0080.png)
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- BERTHOUD E. L'influence de l'irgapyrine sur les fonctions rénales. Helv Med Acta. 1952 Oct;19(4-5):428–433. [PubMed] [Google Scholar]
- DUPONT P., DUCKERT-MAULBETSCH A., FABRE J. Modifications du metabolisme électrolytique et des fonctions glomérulaire et tubulaire sous l'influence des dérivés pyrazolés, irgapyrine et butazolidine. Helv Med Acta. 1952 Dec;19(6):528–546. [PubMed] [Google Scholar]
- GREEN J., WILLIAMS P. O. Effect of butazolidine on the excretion of water and electrolytes. Lancet. 1953 Mar 21;1(6760):575–577. doi: 10.1016/s0140-6736(53)91698-5. [DOI] [PubMed] [Google Scholar]
- GUTMAN A. B., YU T. F. Current principles of management in gout. Am J Med. 1952 Dec;13(6):744–759. doi: 10.1016/0002-9343(52)90374-4. [DOI] [PubMed] [Google Scholar]
- KIDD E. G., BOYCE K. C., FREYBERG R. H. Clinical studies of phenylbutazone (butazolidin) and butapyrin (irgapyrin) in rheumatoid arthritis, rheumatoid spondylitis, and gout. Ann Rheum Dis. 1953 Mar;12(1):20–24. doi: 10.1136/ard.12.1.20. [DOI] [PMC free article] [PubMed] [Google Scholar]
- KUZELL W. C., SCHAFFARZICK R. W., BROWN B., MANKLE E. A. Phenylbutazone (butazolidin) in rheumatoid arthritis and gout. J Am Med Assoc. 1952 Jun 21;149(8):729–734. doi: 10.1001/jama.1952.02930250011004. [DOI] [PubMed] [Google Scholar]
- SIROTA J. H., YU T. F., GUTMAN A. B. Effect of benemid (p-[di-n-propylsulfamyl]-benzoic acid) on urate clearance and other discrete renal functions in gouty subjects. J Clin Invest. 1952 Jul;31(7):692–701. doi: 10.1172/JCI102651. [DOI] [PMC free article] [PubMed] [Google Scholar]
- WILKINSON E. L., BROWN H. The effect of butazolidin (phenylbutazone) on water and electrolyte excretion. Am J Med Sci. 1953 Feb;225(2):153–158. doi: 10.1097/00000441-195302000-00007. [DOI] [PubMed] [Google Scholar]